ArticleJugan geon-gang gwa jilbyeong2025
[Tuberculosis Notification Status in the Republic of Korea, 2024].
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Changes in Sero-immunological Status for Infectious Diseases in Solid Organ Transplantation: A 20-Year Single-Center Study in Korea.Annals of laboratory medicine · 2026Article
- Tuberculosis-Related Hospitalization According to Comorbidity Burden: A Retrospective Single-Center Cohort Study.Tropical medicine and infectious disease · 2026Article
- Comparative tuberculosis risk in healthcare and educational workers: occupational synergy.ERJ open research · 2026Article
- Overview of Tuberculosis Cases Reported in 2024 in the Capital Region: Seoul Metropolitan City, Incheon Metropolitan City, Gyeonggi-do, and Gangwon State.Jugan geon-gang gwa jilbyeong · 2026Article
- Operational Overview and Implementation Challenges of Misokkumteo, a National Tuberculosis Care Facility (2011-2024).Public health weekly report · 2026Review
- The Tuberculosis Relief Belt Project in the Republic of Korea: A 10-Year Review of Performance and Future Directions (2014-2024).Public health weekly report · 2026Review
- [Commemoration of the Special Issue on Tuberculosis in "Jugan geon-gang gwa jilbyeong · 2025Article
- Cohort profile: the KDCA-Tuberculosis-NHIS cohort linking tuberculosis surveillance and health insurance data in Korea.Epidemiology and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tuberculosis (TB) is an airborne infectious disease that is preventable and curable. In the Republic of Korea (ROK), it is designated as a Class 2 infectious disease and is managed. This study aims to describe the incidence and epidemiological characteristics of TB cases in ROK in 2024. Methods: The TB incidence in ROK was compiled based on the annual report on the notified tuberculosis in 2024 and the microdata from 2022 to 2024. The TB incidence rate was calculated using the mid-year registered resident population, the number of foreign residents, and the population covered by medical insurance. Results: In 2024, the number of TB cases in the ROK was 17,944 (35.2 cases per 100,000 population), a decrease of 8.2% from 2023 (n=19,540, 38.2 cases per 100,000 population). Among TB cases aged 65 years and older, 10,534 were reported in 2024, a decrease of 6.9% from 2023 (n=11,309). However, the proportion of TB cases aged 65 and older increased to 58.7% (an increase of 0.8% point compared with 2023), continuing an upward trend since 2000. The number of TB cases who are foreigners in 2024 was 1,077, a decrease of 2.7% from 2023 (n=1,107), but the proportion of foreign TB cases increased to 6.0% from 5.7% in 2023. Conclusions: In 2024, the number of TB cases in the ROK decreased by 8.2% compared to 2023. However, the proportion of elderly TB cases aged 65 and older and foreign TB cases increased. Korea Disease Control and Prevention Agency keeps implementing TB prevention and control programs for high-risk groups and vulnerable populations to address emerging challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.